Pro Medicus Ltd
PME
Company Profile
Business description
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.
Contact
450 Swan Street
RichmondVIC3121
AUST: +61 394298800
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
30 June 2025
Employees
75
Stocks News & Analysis
etfs
Aussie investors sour on this ETF
Investors retreat despite positive market sentiment for the asset class.
stocks
Should you avoid this highflying ASX share?
A sound business model but the shares are expensive.
personal-finance
Bookworm: A timely reminder of what can drive a market reversal
David Dreman sought to beat the market by going against the crowd. The mechanisms behind that could explain Nvidia's recent fall.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,713.68 | 51.43 | -0.66% |
| DAX 40 | 23,526.80 | 244.65 | -1.03% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,859.64 | 25.28 | -0.28% |
| HKSE | 23,892.56 | 142.82 | -0.59% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,377.00 | 25.66 | -0.75% |